Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers S M Kirby, J Smith, G P Ventresca Abstract Background -Metered dose inhalers for the treatment of asthma use chlorofluorocarbons as propellants. These face an international ban due to their effect on the ozone layer. Salmeterol has been reformulated using the non-chlorinated propellant Glaxo inhalation grade HFA134a. Methods -The safety, tolerability and systemic pharmacodynamic activity of the salmeteroIVHFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design. Results Studies in animals have shown HFA134a to be a non-toxic, inert compound. It was well tolerated when given alone to healthy subjects in single and repeat doses up to a maximum of 10 actuations four times daily for 14 days.2 HFA134a is rapidly absorbed following inhalation, and rapidly eliminated from the body by ventilation, with no evidence of accumulation or significant metabolism. 3 We have investigated the safety and tolerability of the salmeterol/HFA134a inhaler in healthy subjects and compared its systemic pharmacodynamic activity with that of the current salmeterol inhaler using chlorofluorocarbon propellant 1 Cumulative dose (ig) Figure 2 Mean (SE) plasma potassium levels before and after cumulative doses of the salmeterollHFA134a inhaler (0), the salmeterol/P11/12 inhaler (7, and placebo (A) in 12 subjects.
and 200 jg at 60 minute intervals giving totals of 50, 100, 200, and 400 jg. The standard inhalation technique without a spacer was used. The systemic pharmacodynamic response tc salmeterol was determined by measuring pulse rate and blood pressure, tremor, QT, interval from a 12-lead ECG and rhythm strip, plasma levels of potassium and glucose, before dosing and at 30 and 55 minutes after each dose. Adverse events were recorded and special attention was paid to any cough and/or throat irritation at dosing. Routine laboratory safety screens were performed before and after the study and at the start of and 24 hours after each study day.
Each parameter was summarised by the final value after the last dose and the slope of linear regression of the dose-response curve (using means of values obtained at 30 and 55 minutes). Both were analysed using analysis of variance. The study had at least 90% power to confirm the equivalence ofthe two salmeterol treatments based on the 95% confidence intervals for the mean difference between them lying within + 10 beats/min for pulse rate and + 0 3 mmol/l for plasma potassium levels.
Results
The systemic pharmacodynamic response to the salmeterol/HFA134a inhaler was related to the dose over the dose range used; comparison of the salmeterolIHFA134a inhaler with placebo gave significant differences for the final values and the slope for all parameters measured ( figs 1 and 2) .
Comparison between the two salmeterol inhalers showed no significant differences, except for the final value of plasma levels of potassium ( the most common device for portable treatment and the pharmaceutical industry is committed to their reformulation without chlorofluorocarbons. Salmeterol formulated with a chlorine-free hydrofluoroalkane, HFA1 34a, appeared to be at least as safe and well tolerated by healthy subjects as the current salmeterol inhaler, even at 4-8 times the standard therapeutic dose. Adverse events were rare and mild. There was very little cough or irritation at dosing, seen only with the highest number of actuations -a not unusual finding with metered dose inhalers, especially when many actuations are taken in rapid sequence. The administration of HFA134a did not appear to alter the safety and tolerability profile of salmeterol and there was no indication of any interaction; in particular, HFA1 34a did not appear to sensitise the cardiovascular system to the effects of salmeterol.
When administered in large doses inhaled 2 adrenoreceptor agonists are associated with tremor and changes in cardiovascular, metabolic, and biochemical parameters. In healthy subjects these effects reach maximal levels one hour after administration of salmeterol. 4 In this study the systemic pharmacodynamic response to salmeterol was investigated with sensitive and clinically relevant parameters using a series of cumulative doses, spanning and exceeding the range in clinical use, to maximise the chances of revealing differences between formulations.
The only significant difference between the two salmeterol inhalers was observed on the final value of plasma levels of potassium which was smaller (0O 12 mmol/l) than the predetermined criterion of clinical significance (O 3 mmol/l). The observed effect was less with the salmeterol/HFAI34a inhaler and is likely to be a chance finding. This small difference in one sensitive systemic parameter is unlikely to be reflected in any substantial change in the clinical profile of the drug.
